FBRX

Forte Biosciences, Inc. FBRX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $18.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-23.33M

Quarter to Jun 30

Free cash flow

$-22.70M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$432.73M total
FEDERATED HERMES, INC.
$44.85M+19.5%
ORBIMED ADVISORS LLC
$33.53M+31.8%
FRED ALGER MANAGEMENT, LLC
$30.59M+13.0%
Jupiter Topco LLC
$29.20M--
BlackRock, Inc.
$25.99M+1755.0%
Affinity Asset Advisors, LLC
$24.34M+13.2%
MPM BioImpact LLC
$20.98M-1.3%
TCG Crossover Management, LLC
$19.55MNew
VANGUARD CAPITAL MANAGEMENT LLC
$18.31M+62.1%
Woodline Partners LP
$15.15M+114.7%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$14.88M-26.3%
Integral Health Asset Management, LLC
$14.34M+350.0%
MILLENNIUM MANAGEMENT LLC
$13.92M+93.9%
CITADEL ADVISORS LLC
$11.63M+134.6%
FMR LLC
$10.69M+47.6%
GEODE CAPITAL MANAGEMENT, LLC
$10.06M+277.3%
AMERIPRISE FINANCIAL INC
$8.90M+274.7%
Cable Car Capital, LP
$8.50M0.0%
STATE STREET CORP
$6.98M+499.3%
Candriam S.C.A.
$6.43M+257.4%
Boxer Capital Management, LLC
$5.83MNew
Trails Edge Capital Partners, LP
$5.81MNew
SPHERA FUNDS MANAGEMENT LTD.
$5.31M+35.0%
Squadron Capital Management LLC
$4.78MNew
AWM Investment Company, Inc.
$4.73M+11.2%
See all 86 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FBRX

Earnings Per Share

13fpro.ai/company/FBRX

Loading ratio trend…

FBRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Forte Biosciences, Inc.'s annual filings on SEC EDGAR.

Forte Biosciences, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2019$36.0K$-4.1M—
FY 2018$18.0M$-49.0M—
FY 2017$41.0K$-38.9M—
FY 2016$49.0K$-33.5M—
Source: FBRX filings on SEC EDGAR →

FBRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Forte Biosciences, Inc. (FBRX): stock profile, AI score and financials

Forte Biosciences, Inc. (FBRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. FBRX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $18.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Forte Biosciences, Inc. reports net income of $-23.3M, free cash flow of $-22.7M. Top institutional holders of FBRX by reported 13-F value include FEDERATED HERMES, ORBIMED ADVISORS, FRED ALGER MANAGEMENT, based on the most recent SEC filings. FBRX trades on the Nasdaq exchange and files with the SEC under CIK 1419041. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FBRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Forte Biosciences, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1419041 →